Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study.
Banach M, Lewek J, Pol K, Rabczenko D, Balanescu SM, Blaha V, Ceska R, Jankowski P, Surma S, Kolovou G, Liberopoulos E, Mitu F, Mitu M, Naji FH, Paragh G, Popławska M, Vrablik M, Pella D.
Banach M, et al. Among authors: surma s.
Front Cardiovasc Med. 2023 Jun 19;10:1206551. doi: 10.3389/fcvm.2023.1206551. eCollection 2023.
Front Cardiovasc Med. 2023.
PMID: 37404744
Free PMC article.